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Abstract
Velo-cardio-facial syndrome is one of the names that has been attached to one of the most common
multiple anomaly syndromes in humans. The labels DiGeorge sequence, 22q11 deletion syndrome,
conotruncal anomalies face syndrome, CATCH 22, and Sedlačková syndrome have all been attached
to the same disorder. Velo-cardio-facial syndrome has an expansive phenotype with more than 180
clinical features described that involve essentially every organ and system. The syndrome has drawn
considerable attention because a number of common psychiatric illnesses are phenotypic features
including attention deficit disorder, schizophrenia, and bipolar disorder. The expression is highly
variable with some individuals being essentially normal at the mildest end of the spectrum, and the
most severe cases having life-threatening and life-impairing problems. The syndrome is caused by
a microdeletion from chromosome 22 at the q11.2 band. Although the large majority of affected
individuals have identical 3 megabase deletions, less than 10% of cases have smaller deletions of 1.5
or 2.0 megabases. The 3 megabase deletion encompasses a region containing 40 genes. The syndrome
has a population prevalence of approximately 1:2,000 in the U.S., although incidence is higher.
Although initially a clinical diagnosis, today velo-cardio-facial syndrome can be diagnosed with
extremely high accuracy by fluorescence in situ hybridization (FISH) and several other laboratory
techniques. Clinical management is age dependent with acute medical problems such as congenital
heart disease, immune disorders, feeding problems, cleft palate, and developmental disorders
occupying management in infancy and preschool years. Management shifts to cognitive, behavioral,
and learning disorders during school years, and then to the potential for psychiatric disorders
including psychosis in late adolescence and adult years. Although the majority of people with velo-
cardio-facial syndrome do not develop psychosis, the risk for severe psychiatric illness is 25 times
higher for people affected with velo-cardio-facial syndrome than the general population. Therefore,
interest in understanding the nature of psychiatric illness in the syndrome remains strong.
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INTRODUCTION
Velo-cardio-facial syndrome (VCFS) is one of the most common multiple anomaly syndromes
in humans. The syndrome’s pattern of inheritance was confirmed to be autosomal dominant in
reports in the 1980s [Shprintzen et al., 1981; Williams et al., 1985] and its specific genetic
cause was found in 1992 when a microdeletion of chromosome 22 at band q11.2 was described
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[Scambler et al., 1992]. Several other reports followed that confirmed the microdeletion
[Driscoll et al., 1992; Kelly et al., 1993]. VCFS has several other labels that have been applied
in a variety of literature sources around the world. As a result, some clinicians and researchers
mistakenly believe that each label represents a separate and specific syndrome each caused by
the same deletion from chromosome 22 [Robin and Shprintzen, 2005]. These disorders include
DiGeorge sequence (often mistakenly labeled as DiGeorge syndrome), Sedlačková syndrome,
conotruncal anomalies face syndrome, and Cayler syndrome [Robin and Shprintzen, 2005;
Shprintzen, 2005b and c]. Other names that have been applied include 22q11 deletion syndrome
and CATCH 22. Although 22q11 deletion syndrome has been adopted by some clinicians and
researchers, it has not gained universal acceptance in much the same way that trisomy 21 is
used less frequently than Down syndrome to describe that disorder. Velo-cardio-facial
syndrome is descriptive of the clinical presentations and is preferred in many circles. CATCH
22 has been decried as an attempt at humor at the expense of affected individuals. Catch 22 is
the title of a black humor novel by Joseph Heller and is a term reserved for a “no-win” situation,
or an impossible circumstance with no solution [Robin and Shprintzen, 2005], something that
is clearly inappropriate for a syndrome like VCFS that can often be treated very effectively.
As discussed by Robin and Shprintzen [2005], an individual with a deletion from chromosome
22 at band q11.2 has VCFS (22q11 deletion syndrome or whatever other label you choose)
and if there is no deletion, then the individual does not have the syndrome. It is also true that
any diagnostic label that involves the same 22q11.2 deletion represents exactly the same
disorder regardless of the name [Robin and Shprintzen, 2005; Shprintzen, 2005b and c].
Although this may seem to be a trivial point, it is not at all. For example, Opitz syndrome (also
known as B/GGG syndrome) was reported erroneously to be caused by the same deletion of
chromosome 22 as VCFS [McDonald-McGinn et al., 1995; Fryburg et al., 1996]. The
distinction between the two syndromes is important because the diagnostic and treatment
implications are significant. Opitz syndrome has specific anomalies of the larynx and
esophagus that do not occur in VCFS, but VCFS has anomalies of the larynx different from
those in Optiz syndrome [Chegar et al., 2006]. The diagnosis and management of laryngeal
cleft or tracheoesophageal fistula, which do occur in Opitz syndrome but do not in VCFS,
would be completely different than the management of laryngeal web and laryngomalacia that
occur in VCFS. The interpretation of “esophageal abnormalities” as consistent with VCFS is
erroneous in nearly all cases. Anomalies of the internal carotid arteries do occur in VCFS, but
not in Opitz syndrome. Most importantly, a strong link to psychiatric illness has been
established in VCFS, but not in Opitz syndrome. Therefore, diagnostic errors can result in
potentially dangerous decisions about management based on the presumed phenotypic
spectrum of the syndrome. Although feeding difficulties occur in both VCFS and Opitz
syndrome, the structural malformations that lead to them are entirely different.
The use of different names for the same condition is not new in the field of clinical genetics.
Besides the previously mentioned Down syndrome and trisomy 21, many other nosologic
variations exist. There is no specific system of taxonomy in the naming of syndromes. There
are many examples of disorders that have eponyms, including Wolf-Hirschhorn syndrome,
Williams syndrome, Angelman syndrome, Prader-Willi syndrome, and Kallmann syndrome
to name a few. On occasion, a single syndrome will have multiple eponyms, including Williams
syndrome (also called Beuren-Williams syndrome by some), or Treacher Collins syndrome
(also known as Franceschetti syndrome), but VCFS may be unique in having five eponyms
assigned to it (Shprintzen syndrome, DiGeorge syndrome, Cayler syndrome, Takao syndrome,
and Sedlačková syndrome). Some syndromes have their names linked to their causes, although
this has caused some problems with syndromes that are etiologically heterogeneous. Besides
22q11 deletion syndrome, there is trisomy 13, trisomy 18, amnion rupture sequence, fetal
alcohol syndrome, retinoic acid embryopathy, homocystinuria, and phenylketonuria. It is
curious that most microdeletion syndromes have escaped this classification system (so that
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Williams syndrome and Prader-Willi syndrome are not called 7q11.23 deletion syndrome or
15q11 – 13 deletion syndrome respectively), but for some reason VCFS has not. Other
syndromes are named symptomatically (often with acronyms), including branchio-oto-renal
syndrome (BOR), ectrodactyly, ectodermal dysplasia and clefting syndrome (EEC), and
cardio-facial-cutaneous syndrome (CFC). Many syndromes have names that cover two or more
of these nosologic systems so that their names may be either symptom based, eponyms, or
causation, such as branchio-oto-renal syndrome (also known as Melnick-Fraser syndrome),
Treacher Collins syndrome (also known as mandibulofacial dysostosis), neurofibromatosis
type 1 (von Recklinghausen disease), and Apert syndrome (acrocephalosyndactyly); but VCFS
covers all of those categories and within the eponym category has multiple names. The
differences relate to place of training (calling it what your professor called it), geographic
location (it is more likely to be Sedlačková syndrome in the Czech Republic and conotruncal
anomalies face syndrome in Japan), and politics (not using the name your competitor uses).
Regardless, all of these names refer to exactly the same syndrome, and the confusion over the
nosology has unfortunately resulted in clinical confusion, as well. As a personal bias (keeping
in mind that one of the eponyms includes my difficult to spell and difficult to pronounce last
name) VCFS is simply easier to say and write and communicate than any of the other labels
and its use should therefore be encouraged.
Diagnostic Criteria
VCFS has an extremely expansive phenotypic spectrum. More than 180 clinical features, both
physical and behavioral, have been described [Robin and Shprintzen, 2005; Shprintzen,
2005a and b; VCFS Educational Foundation, 2007]. No single clinical feature occurs in 100%
of cases and there is no reported case of the syndrome that has all or even most of the clinical
findings. The phenotype therefore shows markedly variable expression. The diagnosis is
therefore defined by the deletion of DNA from chromosome 22 at the q11.2 band spanning the
region that is regarded as the critical region (see below). The diagnostic procedures used to
identify the deletion are highly reliable and for all practical purposes can be regarded as close
to 100% reliable [Robin and Shprintzen, 2005; Shprintzen, 2005b and c]. At this time, FISH
(Fluorescence In Situ Hybridization) is the most commonly used and most easily accessible
diagnostic procedure. FISH is a procedure that uses DNA probes to determine if a specific
region of the genome, in this case the 22q11.2 region, is present in two copies in a chromosome
preparation obtained from peripheral blood that has been denatured to allow hybridization of
a probe specific to the site in question. As noted in Figure 1, only one copy of the chromosome
22q11.2 region is present. FISH for a 22q11.2 deletion is essentially accurate 100% of the time
[Robin and Shprintzen, 2005]. If a deletion is not detected, then the patient does not have VCFS,
and if a deletion is present, then the patient does have VCFS. Other molecular genetics tests
will clearly become widely available in the near future, such as microarray analysis and MLPA,
but at the current time, FISH is widely available, relatively cost effective, and highly accurate.
Some clinicians rely on minimal diagnostic criteria or a probability approach to diagnosing
genetic syndromes. Using this type of approach, it is possible that someone who has a tetralogy
of Fallot, cleft palate, mental retardation, immune disorder, hypotonia, developmental delay,
and small ears with overfolded helices could have VCFS. Unfortunately, I was describing an
individual with Down syndrome. There are multiple syndromes that present with this
combination of anomalies, and even if the list were increased in complexity, there would still
be significant phenotypic overlap between a large number of syndromes. Syndromic diagnosis,
or even syndromic suspicion is dependent on experience and the ability to use sound deductive
reasoning to reach a conclusion, much the same way that Sherlock Holmes solved mysteries.
Although the diagnosis depends on the positive FISH test for the deletion, one must still use
deductive reasoning to refer for the test unless all patients with a particular condition, such as
tetralogy of Fallot, are screened for VCFS. Because VCFS does not involve facial dysmorphism
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in most cases (Figure 2), there is not as distinctive a facial appearance as in Down syndrome
or Williams syndrome. When originally published, the facial appearance was called “typical”
meaning that the original dozen cases resembled each other, but not that the appearance was
abnormal, per se. Therefore, children with VCFS do not call attention to themselves as do cases
with noticeable facial dysmorphisms. It is important for clinicians to become familiar with the
“gestalt” of the diagnosis of VCFS unlike Down syndrome that is easily recognized by even
inexperienced clinicians.
The decision to perform FISH for the diagnosis of VCFS depends on clinical suspicion.
Screening of newborns with interrupted aortic arch, type B, tetralogy of Fallot, and truncus
arteriosus are clearly indicated because of the high yield these anomalies will produce.
However, one must keep in mind that the most common heart anomaly in VCFS is ventricular
septal defect (VSD) although VCFS cases make up a small percentage of people with VSD.
Therefore, children with VSD should be examined by an experienced clinical geneticist to
determine if FISH testing is indicated. Among children with hypernasal speech or cleft palate,
the yield will be somewhat lower than for major heart anomalies. Therefore, it is necessary to
determine if other anomalies are present that would indicate the presence of a multiple anomaly
syndrome that might be consistent with VCFS. The presence of asymmetric facial animation,
characteristic ears, hypotonia, or any of the other anomalies consistent with VCFS would
increase the level of suspicion. The more anomalies that are present, the higher the probability
that FISH will be positive. However, there is no substitute for clinical judgment and the power
of solid deductive reasoning.
The Prevalence and Incidence of VCFS
There have been a number of reports citing the prevalence or incidence of VCFS with estimates
ranging from approximately 1:2000 to approximately 1:7000. Data relating to population
statistics are highly dependent on the method of ascertainment of the disease. A large
percentage of previous reports were based on birth records, reports of infant examinations, or
reports of anomalies from multiple sources that were not controlled for quality or reliability
[Ryan et al., 1997; Óskarsdóttir et al., 2004]. Because VCFS is a developmental disorder with
clinical findings that are not apparent until later in life, many of the major findings are not
evident or detectable at birth or in infancy. At least 30% of cases do not manifest cardiac
malformations, and many of those with heart anomalies have silent anomalies, such as right-
sided aortic arch that cannot be detected without specifically looking for them. It is probable
that at least one-third if not nearly one-half of cases are not diagnosed until later in life and
that many cases go undetected.
It is also likely that population prevalence varies with place of birth. Because of the high
frequency of severe and life-threatening congenital heart disease associated with VCFS, it is
likely that many children born with the syndrome in areas where there is not good access to
good surgical care and neonatal intensive care units that many babies with VCFS do not survive
the neonatal period. In most developed and medically sophisticated countries, a very high
percentage of children with even very severe heart malformations survive. Therefore,
population prevalence in nations with access to pediatric cardiothoracic surgeons and intensive
care units might have twice the population prevalence compared to developing or undeveloped
nations where such care is not uniformly available.
It is also true that population prevalence for VCFS is not as high as incidence of the syndrome.
It is known that VCFS triggers several developmental sequences that are incompatible with
life, including Potter sequence and holoprosencephaly sequence [Devriendt et al., 1997; Wraith
et al., 1985]. Some neonates with VCFS who have pulmonary atresia in association with major
heart anomalies also do not survive [Michielon et al., 2006]. Some fetal death associated with
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these factors is also to be expected. Therefore, the overall frequency of nonsurviving
pregnancies, although not known, may be relatively high.
Over the past several years, it has become clear to us that the frequency of VCFS among all
surviving newborns in our area is at least 1:2000. This can be stated with a high degree of
certainty because our entire region of Central New York has one pediatric cardiology group,
one pediatric cardiothoracic surgeon, and one craniofacial center and these practitioners send
all of their patients to The VCFS International Center. Based on these data alone with
approximately 10,000 births per year in the region covered by our institution, and an average
of five neonates per year with VCFS identified from that sample, the ascertainment would be
1:2,000. However, if we factor in babies without congenital heart disease, without overt or
obvious submucous cleft palate, there are likely to be nearly one-quarter of the cases that are
not detected in infancy (based on the frequency of heart and palate anomalies in VCFS).
Therefore, our estimate would put the true population prevalence at approximately 1:1600.
This statistic is approximately consistent with our previous report of 1:2000 [Shprintzen,
2005b].
Clinical Features and the VCFS Phenotype
Because VCFS is so common among genetic disorders, many cases have been seen and the
phenotype studied from a variety of disciplines including heart, craniofacial, behavioral,
vascular, central nervous system and more. More than 180 distinct clinical phenotypes have
been described and reported impacting nearly every organ system and developmental function.
Table 1 lists the clinical phenotype by category. None of the findings are obligatory, and some
occur with low frequency as noted in the table. However, the low frequency anomalies occur
at a rate higher than seen in the general population.
There are certain clinical features that can be used as strong indications for suspecting VCFS
as the diagnosis that would prompt clinicians to refer their patients for diagnostic lab
procedures. Congenital heart disease is present in approximately 70% of cases and the type of
heart anomalies may lead to stronger suspicion of VCFS than any other diagnosis. VCFS
constitutes a high percentage of conotruncal heart anomalies including more than half of all
cases of interrupted aortic arch, type B. More than 15% of newborns with tetralogy of Fallot,
slightly less than half of truncus arteriosus cases, and approximately one-third of posterior
malalignment ventricular septal defects [Goldmuntz et al., 1998]. The most common heart
anomaly found in individuals with VCFS is ventriculoseptal defect, but because VSD is such
a common malformation, the percentage of people with VSD who have VCFS is small. Given
the high frequency of VCFS among individuals with conotruncal anomalies, newborns with
these types of heart anomalies should be screened with FISH if they do not present with another
obvious syndrome such as Down syndrome or trisomy 13. It has now been confirmed that
hemizygosity for the gene TBX1 is responsible for the cardiac phenotypes in VCFS [Merscher
et al., 2001].
VCFS is also common among children with palatal anomalies. Although initially reported as
a common finding in children with cleft palate [Shprintzen et al., 1978], the most common
forms of palatal anomalies in VCFS are submucous cleft palate and occult submucous cleft
palate [Shprintzen, 1982, 2000bShprintzen, 2005]. These clefts can be very difficult to identify
without state-of-the-art diagnostic procedures such as nasopharyngoscopy. It is for this reason
that several reports have significantly underestimated the frequency of clefting, especially
when data regarding anomalies has been ascertained from birth records or multiple sources
with varying levels of diagnostic expertise [Ryan et al., 1997; Óskarsdóttir et al., 2004]. More
specifically, occult submucous cleft palate is an anomaly largely unknown to clinicians who
do not specialize in the diagnosis of palatal anomalies. It is for this reason that many reports
Shprintzen Page 5













suggest that individuals with VCFS have “short palates” or hypernasal speech in the absence
of a cleft. However, occult submucous cleft palate is an identifiable anomaly that is a form of
cleft palate that often goes undetected because it requires endoscopic examination of the nasal
surface of the velum [Shprintzen, 1982, 2000bShprintzen, 2005]. It has also been found that
there is a high frequency of palatal and pharyngeal asymmetry in VCFS that can also only be
determined by endoscopic assessment [Chegar et al., 2006]. Among the anomalies seen in the
pharynx are major vascular anomalies including abnormal placement of the internal carotid
arteries [MacKenzie-Stepner et al., 1987; Mitnick et al., 1996; Tatum et al., 2002] and tortuous
or kinked vertebral arteries [Mitnick et al., 1996]. These vascular anomalies have been cited
as potentially dangerous risks when pharyngeal surgery is being planned [MacKenzie-Stepner
et al., 1987; Mitnick et al., 1996; Tatum et al., 2002]. It has also been reported that the muscle
tissue in the pharynx has abnormally small fiber size and abnormal distribution of fiber type
[Zim et al., 2003]. All of these factors have been cited as risk factors for the development of
velopharyngeal insufficiency and hypernasal speech.
The vascular anomalies of the pharynx may represent one of a number of vascular anomalies
associated with VCFS. Major anomalies of the chest vessels [Shprintzen et al., 1978; Young
et al., 1980; Shprintzen, 2005b; VCFS Educational Foundation, 2007], neck vessels
[MacKenzie-Stepner et al., 1987; Mitnick et al., 1996; Shprintzen, 2000b; Tatum et al.,
2002], and brain vasculature [Shprintzen, 2000a] have all been reported in individuals with
VCFS. It has been hypothesized that the large number of vascular anomalies in VCFS in major
vessels may result in a number of developmental sequences [Shprintzen et al., 1997], a notion
supported by reports of Robin sequence [Shprintzen, 1988; Shprintzen and Singer, 1992],
DiGeorge sequence [Robin and Shprintzen, 2005; Shprintzen, 2005b], Potter sequence
[Devriendt et al., 1997] and holoprosencephaly sequence [Wraith et al., 1985] in individuals
with VCFS.
A large number of other structural anomalies have been reported in association with VCFS
including ocular anomalies [Mansour et al., 1987], cranial anomalies [Arvystas and Shprintzen,
1984], limb anomalies [Ming et al., 1998], meningomyelocele [Nickel et al., 1994], anal
anomalies [Worthington et al., 1997], platelet anomalies [Van Geet et al., 1998], brain
anomalies [Worthington et al., 2000; Eliez et al., 2001; Kates et al., 2004; Antshel et al.,
2005; Kates et al., 2006a and b; Schaer et al., 2006; Debbane et al., 2006], renal anomalies
[Czarnecki et al., 1998; Shprintzen, 2005b], spine and skeletal anomalies [Ricchetti et al.,
2004], thyroid disorders [Kawame et al., 2001], and hypoparathyroidism [Hieronimus et al.,
2006]. In all, over 180 separate anomalies or developmental sequences have been reported in
association with VCFS covering nearly every organ and system [Robin and Shprintzen,
2005; Shprintzen, 2005b; Shprintzen, 2000a; VCFS Educational Foundation, 2007]. However,
the anomalies that have attracted the greatest amount of attention are the behavioral and
developmental disorders common to VCFS.
The initial report of psychiatric disorders in VCFS was published in 1992 [Shprintzen et al.,
1992] and coincided with the identification of the deletion from 22q11.2 [Scambler et al.,
1992]. This coincidence sparked substantial research interest because of the notion that a gene
that would influence psychiatric phenotypes resided in the deleted region. The search for this
influence has continued unabated ever since with focus on a number of candidate genes,
including but not limited to COMT [Lachman et al., 1996; Graf et al., 2001; Gothelf et al.,
2005] and PRODH [Shprintzen, 2005a; Li et al., 2004]. There has also been substantial research
focusing on brain structure and function in VCFS [Worthington et al., 2000; Eliez et al.,
2001; Kates et al., 2004; Antshel et al., 2005; Kates et al., 2006a and b; Schaer et al., 2006;
Debbane et al., 2006]. Reductions in both grey and white matter volumes have been
documented with anomalous characteristics of the corpus callosum, the amygdala, the caudate
nucleus, and temporo-parietal regions of the brain. It is not yet clear what biologic basis of
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mental illness in VCFS, but it is clear that the syndrome presents an excellent model for
understanding psychiatric disorders, especially psychosis, in humans. The rate of psychosis in
VCFS is more than 25 times greater than it is in the general population. It is therefore almost
certain that a genomic factor or factors in the deleted region exert some control over brain
development and/or function. Because the large majority of individuals with VCFS have 40
genes deleted, the process of determining the specific factor involved is complicated and the
search is continuing. There have, however, been some promising outcomes that may have
broader implications for the general population.
One gene that may play an important role is COMT (catechol-O-methyltransferase). COMT is
responsible for degrading catecholamines, including dopamine and epinephrine, two major
neural transmitters. Once released into the synapses of the brain, catecholamines must be
catabolized in order to avoid having an elevated level of these substances that could interfere
with normal brain function. COMT sits close to the middle of the deleted region in VCFS and
one copy of COMT is deleted in all individuals with VCFS. Polymorphisms in COMT may
also play a role in the severity of psychiatric illness. Two polymorphisms that have been studied
include a low activity allele (COMT158met) and a high activity allele (COMT158val) [Lachman
et al., 1996] and the association of the most severe form of mental illness in adults with VCFS
has been reported to occur when a single copy of the COMT158met allele is present [Lachman
et al., 1996; Graf et al., 2001]. However, the samples studied to date have been relatively small
and more data is required to determine the contribution of COMT and its polymorphisms to
the development of mental illness.
Speech and language impairment are also common manifestions of VCFS with approximately
75% of affected individuals having hypernasal speech and a high percentage having severe
articulation impairment [Golding-Kushner et al., 1985; Golding-Kushner, 2000; Shprintzen,
2005b; Golding-Kushner, 2007]. Speech onset is usually mildly delayed and receptive
language abilities exceed expressive [Golding-Kushner et al., 1985] although some of the
expressive disorders are related to unintelligible speech and incorrect management of these
disorders in early years [Golding-Kushner, 2000]. However, remediation of these problems
has led to excellent prognosis in the large majority of cases.
Immune disorders are also relatively common, but few cases have severe immunodeficiency.
In the large majority of cases with immune problems, early childhood is marked by frequent
respiratory infections. In most cases, these illnesses present as frequent upper respiratory
infections, middle ear effusions, and sinusitis. In the more severe cases, pneumonia and
bronchitis may present early in life and persist through childhood. The early onset of pneumonia
in VCFS can be confused with aspiration, a rare problem in VCFS [Shprintzen, 2005b].
Children with VCFS often have problems with emesis in infancy and many clinicians
mistakenly believe that emesis is “reflux” and that it can lead to aspiration.
Early feeding problems are also common in VCFS. These problems are multifactorial in
etiology, prompted by hypotonia, congenital heart disease, endocrine disorders, and airway
obstruction secondary to a retruded lower jaw and low muscle tone. Although swallowing
disorders have been reported in VCFS [Eicher et al., 2000], there has been no unifying or
satisfactory explanation for their origin. Although many children with the syndrome have been
treated by long-term gavage feeding and gastrostomy, clinical experience has shown that these
techniques are rarely necessary.
Etiology: Specific or Heterogeneous?
As mentioned earlier, it has now been firmly established that all individuals with VCFS have
a microdeletion from chromosome 22q11.2 [Robin and Shprintzen 2005; Shprintzen, 2005b].
Although two studies have reported that approximately 20% of individuals clinically diagnosed
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with VCFS do not have detectable deletions [Driscoll et al., 1993; Morrow et al., 1995], both
of these studies were flawed by uncontrolled ascertainment of subjects [Robin and Shprintzen,
2005a]. Both studies accepted blood samples for DNA analysis from multiple clinicians at
multiple sites based on their clinical diagnosis without assessing the clinician’s accuracy or
expertise. It is likely that the cases reported to have VCFS who were found to be absent the
deletion were simply clinical errors of judgment.
There is also some degree of diagnostic finesse involved in differentiating syndromic diagnoses
when there are overlapping clinical features. For example, it has been suggested that the same
deletion from chromosome 22 can result in a number of distinctive, separate syndromes, such
as Opitz syndrome [McDonald-McGinn et al., 1995; Fryburg et al., 1996] in addition to VCFS.
There is little doubt that clinical diagnosis is as much an art as a science and as such it is possible
that the molecular science that confirms the diagnosis (such as FISH) is more definitive than
clinical categorization.
The deletion of DNA from 22q11.2 is somewhat variable in the population of individuals with
VCFS. Approximately 90% of affected individuals have a 3 Mb deletion with identical
breakpoints at each end [Morrow et al., 1995; Edelmann et al., 1999]. Fewer than 10% of
individuals with VCFS have smaller nested deletions with the same proximal breakpoint, but
a distal breakpoint that encompasses only 1.5 Mb. It has been reported that there is no difference
in the clinical expression between the 3 Mb and 1.5 Mb deletion [Morrow et al., 1995], but it
may be that subtle differences do exist that have not been studied sufficiently because of the
expansiveness of the phenotype and the number of genes in the deletion.
It is also interesting to note that the variability of expression of VCFS relates even to anomalies
that have had their genomic causes identified. Deletion of the gene TBX1 has been shown to
cause the same spectrum of heart malformations in the mouse as is found in humans. However,
at least 25% of humans with VCFS do not have structural heart anomalies although they are
deleted for TBX1. Is it sufficient to chalk this up to variable expression without offering an
explanation of possible mechanisms that will explain it? It is possible that the deletion of
TBX1 contributes to the heart anomalies but is not the putative cause. It is also possible that
TBX1 is involved in a more complex mechanism of heart development that involves
downstream regulation of other genes or complex genetic interactions of multiple genes. There
is good evidence that TBX1 interacts several genes important to embryogenesis including
several homeobox genes that are highly involved in the regional development of the pharyngeal
arches and pouches that form the structures of the head and neck and portions of the heart and
its vascular system (Merscher et al., 2001; Kelly et al., 2004; Stalmans et al., 2003; Shih et al.,
2007).
Genetic Counseling
VCFS has been established to have an autosomal dominant mode of inheritance. Penetrance
is 100% with highly variable expression. Variable expression is evident even in cases with the
same deletion. The large majority of cases are de novo mutations. Neither parent is affected in
over 90% of cases. This indicates that 22q11.2 is a highly mutable region of the human genome
and that the area is prone to rearrangement. The fact that so many cases represented new
mutations pointed to the possibility of some type of recombination event during stage 1 of
meiosis. This was confirmed and related to a unique evolutionary arrangement of chromosome
22 at the q11.2 band that had four series of low copy repeat DNA sequences within the typically
deleted region (Edelmann et al., 1999). More than 90% of people with VCFS have a deletion
that spans 3 Mb (Morrow et al., 1995). At each end of this typical deletion are identical sets of
low copy repeats (LCRs). The presence of these two sets of LCRs coinciding with the
breakpoints for the deletion directed researchers to discover the mechanism of the deletion to
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be either an interchromosomal recombination error during stage 1 meiosis during
gametogenesis or an intrachromosomal event resulting in material being spliced out of one
copy of the chromosome (Edelmann et al., 1999). The interchromosomal event was found to
be more common (Edelmann et al., 1999). Fewer than 10% of individuals with VCFS inherited
the deletion from an affected parent in our series of more than 1,000 cases.
The variability in the expression of individual traits may have a number of contributing factors,
including polymorphisms in the copies of the genes within the 22q11.2 region on the nondeleted
chromosome. It is also probable that there is downstream and upstream interaction between
genes in the deleted region and genes elsewhere in the genome. Several of these interactions
and regulatory functions have already been reported, including the interactions of TBX1, a
gene always deleted in VCFS, with VEGF, PITX, and FGF10 [Stalmans et al., 2003; Kelly et
al., 2004; Shih et al., 2007]. The role of gene dosage within the 22q11.2 region has been the
subject of many studies within the past decade because of the hope that one or more of the
deleted genes will be found to contribute to psychiatric illness and/or cognitive impairment.
The hope has been that finding this type would lead to a better understanding of mental illness
in general, and potential treatments once the mechanism of mental functioning has been
determined. This research continues, but the possibility that upstream and downstream
regulation may modify deleted genes has complicated the picture considerably.
Management
With over 180 phenotypes associated with VCFS, clinical management is obviously complex.
To date, there has been no indication that congenital heart disease should be treated any
differently in VCFS than other disorders. Success rates are good and seem to be worse in VCFS
only when pulmonary stenosis/atresia are present [Michielon et al., 2006].
Early immune disorders are rarely very severe and in most cases, live viral vaccines can be
administered [Sullivan, 2004]. Illnesses are best treated symptomatically with most infections
being viral. Therefore, overuse of antibiotics should be avoided in order to prevent the
development of opportunistic infections.
Feeding disorders represent a major problem in many infants with VCFS and poor outcomes
for typical treatments may lead to the recommendation for gastrostomy or gavage feedings.
The phenotypic factors that lead to feeding problems in VCFS are hypotonia, vascular
anomalies in the chest, airway compromise, slow clearing of the digestive tract with chronic
constipation, chronic illness, weakness from heart disease, and temperament issues. It is rarely
necessary to perform a gastrostomy in VCFS if appropriate feeding techniques are
implemented, including upright positioning during feedings, increasing the flow from the bottle
by enlarging the hole in the nipple, treating constipation vigorously, and resolving the airway
issues.
Hypernasal speech almost always requires surgical intervention. When cleft palate is present,
it is rare for speech disorders to be successfully resolved with palate repair alone. Secondary
reconstructive surgery is almost always necessary. It has been demonstrated that pharyngeal
flap surgery can be highly effective [Tatum et al., 2002], but an anomalous course of the internal
carotid arteries presents a major risk factor [Mitnick et al., 1996; Tatum et al., 2002]. The use
of preoperative magnetic resonance angiography to locate the internal carotids has been
recommended in children with VCFS [Mitnick et al., 1996; Tatum et al., 2002].
The problem that most concerns parents of children with VCFS is the treatment of behavioral
and psychiatric disorders. The most common early psychiatric disorder in VCFS is ADD. Early
data suggest that low doses of methylphenidate are effective in most cases for controlling ADD
[Gothelf et al., 2003]. There have also been reports that psychosis in VCFS may be treated
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effectively using antidopaminergic medications, including metyrosine [Graf et al., 2001] and
L-methyldopa [O’Hanlon et al., 2003]. To date, outcome studies have been limited to anecdotal
reports, but having a human model for genetically caused mental illness continues to focus
attention on VCFS, and the possibility that COMT plays a major role may help to focus attention
on the dopaminergic system.
Prognosis
The prognosis for the resolution of heart, speech, and immune problems in VCFS is good. The
large majority of babies with VCFS have successful corrections of their heart disease and will
live normal life spans. Immune problems subside with time, and endocrine problems tend to
be intermittent and treatable with appropriate medications. Speech problems respond well to
speech therapy and surgery. Educational issues in VCFS have just begun to receive some
attention in the literature [Landsman, 2007].
There is not yet a substantial data set on the treatment of psychiatric disorders, but the majority
of patients with VCFS do not require medication to treat behavioral disorders. To date, reports
of significant successes with treatments designed to interrupt the abnormal dopaminergic
pathway in VCFS have been limited to a small number of anecdotal reports [Graf et al.,
2001; O’Hanlon et al., 2003]. However, these few reports have been exciting and positive in
their outcomes and will hopefully lead to larger and better controlled studies.
There is not sufficient data as yet to determine the life span of individuals with VCFS. Because
the “modern era” of study of this syndrome is less than two decades old, and the delineation
of the syndrome dates at its earliest to cases described by Sedlačková in 1955, there has not
been an opportunity to study large samples of adults who have reached advanced age. Relying
solely on anecdotal data, our clinical sample contains a number of adults with VCFS in their
seventh decade of life, and we have historical information on a dozen families with three
generations of affected individuals with the first documented case in the family living into the
eighth decade of life. Intuitively, if one were to consider some of the health related issues in
VCFS that might cause early death, such as severe congenital heart disease, severe immune
deficiency, and possible stroke or bleeding disorders from Bernard-Soulier syndrome, an
actuarial table might demonstrate that in aggregate (i.e., mean age of death), people with VCFS
do not have the same life span as nonaffected individuals, but it is probable that people who
live into their early adult years who have not had serious health concerns up to that point will
live a normal life span.
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Fluorescence In Situ Hybridization (FISH) of someone with VCFS (left) compared to a normal
inidivual (right). The FISH on the left shows that one copy of chromosome 22 has only one
fluorescent signal (the control probe) compared to the normal case that has two signals on each
chromosome (control probe and the probe specific to 22q11.2).
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Typical facial appearance in VCFS. Note that although the children in these photos have a
characteristic facial appearance, it is not abnormal.
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